Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSousa, Maria I.pt_PT
dc.contributor.authorSilva, Luís C. V.pt_PT
dc.contributor.authorCorreia, Andreiapt_PT
dc.contributor.authorFreire, Mara G.pt_PT
dc.contributor.authorSilva, Francisca A. ept_PT
dc.contributor.authorPedro, Augusto Q.pt_PT
dc.description.abstractIt is undeniable the potential of messenger RNA (mRNA) vaccines as effective tools to manage infectious disease outbreaks. However, mRNA nanomedicines production is complex and expensive, requiring improved technologies to produce stable and widely accessible products, whilst meeting required production times and fulfilling market demands. Ionic liquids (ILs) are composed of organic cations and organic or inorganic anions. Given their remarkable structural diversity, ILs can be properly designed to improve RNA stability. Moreover, as phase-forming agents of aqueous biphasic systems (ABS), ILs contribute to develop highly selective purification processes. This work aims to integrate production-clarification steps of mRNA vaccines, using thermoreversible IL-based ABS, simplifying subsequent purification steps. Several quality control methods were designed to evaluate integrity and purity of mRNA manufactured resorting to in vitro transcription. ABS formed by dextran from Leuconostoc spp. with an average molecular weight of 450.000-650.000 g/mol (Dex 500) and polyethylene glycol (PEG) 3350 g/mol, containing ILs as adjuvants were characterized regarding their thermoreversible nature. Preliminary mRNA partition experiments using IL-based ABS indicate that mRNA is preferentially partitioned toward the IL-PEG-Rich phase. Promising systems for mRNA purification have been identified. Ongoing work focuses on selecting the most promising IL-based ABS for initial mRNA clarification. In the future, mRNA production-clarification will be integrated into the best performing system to overcome current challenges in mRNA nanomedicine manufacturing, such as sustainability and production speed, whilst improving mRNA stability and yield.pt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50011%2F2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F50011%2F2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0006%2F2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/Concurso de Projetos de Investigação de Caráter Exploratório (PeX) em Todos os Domínios Científicos/EXPL%2FBII-BTI%2F0731%2F2021/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/CEEC IND 2018/CEECIND%2F03076%2F2018%2FCP1559%2FCT0024/PTpt_PT
dc.subjectmRNA nanomedicinespt_PT
dc.subjectIonic liquidspt_PT
dc.subjectThermoreversible aqueous biphasic systemspt_PT
dc.subjectIn vitro transcriptionpt_PT
dc.titleImproving the manufacturing of mRNA nanomedicines using thermoreversible aqueous biphasic systems and ionic liquidspt_PT
ua.event.date7-9 December, 2023pt_PT
degois.publication.titleMicrobiotec’23 - Congress of Microbiology and Biotechnology 2023: book of abstractspt_PT
Appears in Collections:CICECO - Comunicações
DQ - Comunicações

Files in This Item:
File Description SizeFormat 
Sousa et al_2023_Microbiotec_2023.pdf207.74 kBAdobe PDFView/Open

Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.